Antiretroviral Activity of the Anti-CD4 Monoclonal Antibody TNX-355 in Patients Infected with HIV Type 1

Journal of Infectious Diseases

Volumn 189, Issue 2, 2004, Pages 286-291

  Kuritzkes, Daniel R ^a,i   Jacobson, Jeffrey ^b,j   Powderly, William G ^c   Godofsky, Eliot ^d   DeJesus, Edwin ^e   Haas, Frances ^f   Reimann, Keith A ^g   Larson, Jeffrey L ^h   Yarbough, Patrice O ^h   Curt, Valentin ^h   Shanahan Jr , William R ^h  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Bach and Godofsky   (United States)

^e IDC Research Initiative   (United States)

^f Assoc in Med/Mental Health PC   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h Tanox   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j BETH ISRAEL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; MONOCLONAL ANTIBODY; TNX 355; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG INFUSION; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; NOSE CONGESTION; PRIORITY JOURNAL; PRURITUS; RASH; RNA ANALYSIS; SIDE EFFECT; T LYMPHOCYTE; URTICARIA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 9144236197     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/380802     Document Type: Article

References (19)

1. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
2. Richman DD, Bosette SA, Morton SC, et al. The prevalence of antiretroviral drug resistance in the US (abstract LB-17). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:14.
3. Doms RW, Trono D. The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 2000; 14:2677-88.
4. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-85.
5. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfurvitide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-95.
6. Burkly LC, Olson D, Shapiro R, et al. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. J Immunol 1992; 149:1779-87.
7. Burkly LC, Mulrey N, Blumenthal R, Dimitrov DS. Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies. J Virol 1995; 69:4267-73.
8. + cells. J Virol 1992; 66:4784-93.
9. Reimann K, Burkly LC, Burrus B, Waite BCD, Lord CI, Letvin N. In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res Hum Retroviruses 1993; 9:199-207.
10. Reimann K, Lin W, Bixler S, et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997; 13:933-43.
11. Reimann KA, Khunkhun R, Lin W, Gordon W, Fung M. A humanized, nondepleting anti-CD-4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically-infected with simian immunodeficiency virus. AIDS Res Hum Retroviruses 2002; 18:747-55.
12. Boon L, Holland B, Gordon W, et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology 2002; 172:191-203.
13. Kim M, Chen B, Hussey RE, et al. The stoichiometry of trimeric SIV glycoprotein interaction with CD4 differs from that of anti-envelope antibody Fab fragments. J Biol Chem 2001; 276:42667-76.
14. Moldavan M-C, Yachou A, Levesque K, et al. CD4 dimers constitute the functional component required for T cell activation. J Immunol 2002; 169:6261-8.
15. Matthias LJ, Yam PTW, Jiang XM, et al. Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol 2002; 3:727-32.
16. Clark DR, de Boer RJ, Wolthers KC, Miedema F. T cell dynamics in HIV-1 infection. Adv Immunol 1999; 73:301-27.
17. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999; 96:5215-20.
18. Hazan U, Romero IA, Cancello R, et al. Human adipose cells express CD4, CXCR4, and CCR5 [corrected] receptors: a new target cell type for the immunodeficiency virus-1? FASEB J 2002; 16:1254-6.
19. Morel P, Vincent C, Wijdenes J, Revillard JP. Internalization and degradation of anti-CD4 monoclonal antibodies bound to human peripheral blood lymphocytes. Mol Immunol 1993; 30:649-57.